Aesthetic Radiofrequency Associated with Rosmarinus officinalis Supplementation is Safe and Reduces Oxidative Stress in Women: Randomized, and Double-Blind Clinical Trial.
Greissi Tatieli Franke TremêaKarine Raquel Uhdich KleibertLenara Schalanski KrauseAna Paula Weber FellAnais Regina ScapiniKeli Wilchen MarschallCristiano Sartori BaiottoMartha Héllen Tremêa da SilvaJosé Antonio Gonzalez da SilvaChristiane de Fátima ColectPublished in: Journal of evidence-based integrative medicine (2024)
The objective were to evaluate the effects of supplementation of standardized dry extract of Rosmarinus officinalis (RO) and the application of aesthetic radiofrequency on the oxidative stress markers catalase (CAT), superoxide dismutase (SOD), non-protein thiols (NP-SH), and thiobarbituric acid reactive species (TBARS) and the biochemical markers triglycerides, total cholesterol, high density lipoprotein (HDL) cholesterol, glutamic-oxaloacetic transaminase (TGO/AST), pyruvic-glutamic transaminase (TGP/ALT), gamma glutamyl transpeptidase (gamma-GT), and creatinine. This study included 32 women received the aesthetic therapy to reduce localized fat. They were divided into the control group (n = 8) receiving placebo capsules and the intervention group (n = 24) subdivided into Group A, B, and C, each with eight members receiving supplementation with 100, 500, and 1000 mg/day of standardized dry extract of RO, respectively. The Universal Trial Number (UTN) - U1111-1274-6255. Supplementation with RO (500 mg/day) demonstrated a reduction in oxidative stress (quantified with through a significant increase in NP-SH and a reduction in SOD and CAT enzymes). The radiofrequency aesthetic treatment did not promote an increase in oxidative stress; however, it caused significant changes in total cholesterol, HDL cholesterol, and creatinine. RO is a plant with antioxidant effects and its oral consumption is safe in selected women subjects in hepatic and renal markers.
Keyphrases
- oxidative stress
- double blind
- low density lipoprotein
- phase iii
- clinical trial
- high density
- placebo controlled
- phase ii
- polycystic ovary syndrome
- diabetic rats
- ischemia reperfusion injury
- dna damage
- induced apoptosis
- open label
- study protocol
- breast reconstruction
- catheter ablation
- pregnancy outcomes
- randomized controlled trial
- uric acid
- adipose tissue
- breast cancer risk
- cervical cancer screening
- atrial fibrillation
- ultrasound guided
- signaling pathway
- patient satisfaction
- type diabetes
- heat shock
- amyotrophic lateral sclerosis
- hydrogen peroxide
- cell therapy
- anti inflammatory
- bone marrow
- small molecule
- heat stress
- skeletal muscle
- amino acid